ASC22 is an investigational programmed cell death ligand-1 (PD-L1) monoclonal antibody partnered with Alphamab to treat hepatitis B and other viral diseases in Greater China (Alphamab code: KN035).
KN035, as a PD-L1 single domain antibody Fc fusion, has the advantages of subcutaneous injection and good stability at room temperature. These would be of great value to improve patients' compliance and quality of life and to help realize the goal of long-term management of cancer as a chronic disease.
With the close collaboration between Alphamab (together with its affiliate Jiangsu Alphamab Biopharmaceuticals Co., Ltd.) and 3D Medicines (Beijing) Co., Ltd, to date, KN035 has been studied in multiple clinical trials with more than 500 patients exposed in U.S, China and Japan. KN035 has entered into two pivotal trials and demonstrated good safety profile and encouraging preliminary efficacy.
Based on initial studies and the role of PD1/PDL-1 in virus induced immune tolerance，Ascletis and Alphamab hold the view that KN035 has the potential to be one of the best candidates for the immunotherapy of chronic Hepatitis B and other viral diseases.